← Leaderboards
Xianjun Fang
Va Veterans Administration Hospital
$2,749,417
Attributed
$3,772,758
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $413K · FY2005–25$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,772,758 · 3
VA$0 · 1
By mechanism
R01$3,415,079 · 2
R21$357,679 · 1
I01$0 · 1
Top collaborators
- Xiang-Yang Wang5 shared
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingSignal TransductionLinkPathway InteractionsMolecularResponseTumorigenesisMalignant Neoplasm Of OvaryLipidsCellsTumorFatty AcidsEnzymesMalignant NeoplasmsInflammatoryInsightCancer PatientCancer CellPhenotypeAblationMetabolic PathwayAcetyl Coenzyme ACatabolismMetabolism
Grant awards (15)
Novel Function of Ubiquitin-Like Protein 5 As a Fat Suppressor$0
I01 · FY2025 · VA · contact PI
Novel Function of Ubiquitin-Like Protein 5 As a Fat Suppressor$0
I01 · FY2024 · VA · contact PI
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy$404,924
R01 · FY2023 · CA
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy$406,274
R01 · FY2022 · CA
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy$410,049
R01 · FY2021 · CA
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy$413,046
R01 · FY2020 · CA
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy$412,390
R01 · FY2019 · CA
Regulation of lipogenesis by lysophosphatidic acid in ovarian cancer$195,098
R21 · FY2012 · CA · contact PI
Regulation of lipogenesis by lysophosphatidic acid in ovarian cancer$162,581
R21 · FY2011 · CA · contact PI
Lysophosphatidic Acid in Oncogenesis$229,961
R01 · FY2010 · CA · contact PI
Lysophosphatidic Acid in Oncogenesis$229,961
R01 · FY2009 · CA · contact PI
Lysophospholipid in Neovascularization in Ovarian Cancer$219,208
R01 · FY2007 · CA · contact PI
Lysophospholipid in Neovascularization in Ovarian Cancer$225,946
R01 · FY2006 · CA · contact PI
Lysophospholipid in Neovascularization in Ovarian Cancer$231,570
R01 · FY2005 · CA
Lysophospholipid in Neovascularization in Ovarian Cancer$231,750
R01 · FY2004 · CA